Evaluation of the hematological and immunological markers after the first and second doses of BNT162b2 mRNA vaccine
CONCLUSIONS: We can conclude that the Pfizer/BioNTech vaccine produced a more potent T-cell response than humoral ones.PMID:38567619 | DOI:10.26355/eurrev_202403_35766
Source: European Review for Medical and Pharmacological Sciences - Category: Drugs & Pharmacology Authors: M Rafeeq M S Jabir H M Al-Kuraishy Z M A Jeddoa S F Jawad M A A Najm A F Almulla E Elekhnawy J Z Tayyeb A Turkistani B A Alsfouk G E Batiha Source Type: research
More News: Allergy & Immunology | Coronavirus | Covid Vaccine | COVID-19 | Drugs & Pharmacology | Hematology | Pandemics | Pfizer | Vaccines